MétaCan
Menu
← Back to cohort
Record W4406993605 · doi:10.1161/str.56.suppl_1.4

Abstract 4: Thrombolysis with Tenecteplase in Minor Disabling versus Non-disabling Stroke: Secondary Analysis of the TEMPO-2 Trial

2025· article· en· W4406993605 on OpenAlexaff
Yiran Zhang, Brian Buck, Luciana Catanese, Daniel Strbian, Shabnam Vatanpour, Thalia S. Field, Philip Choi, Michael D. Hill, Shelagh B. Coutts

Bibliographic record

VenueStroke · 2025
Typearticle
Languageen
FieldMedicine
TopicAcute Ischemic Stroke Management
Canadian institutionsUniversity of British ColumbiaMcMaster UniversityPopulation Health Research InstituteUniversity of CalgaryUniversity of Alberta
Fundersnot available
KeywordsMedicineTenecteplaseThrombolysisStroke (engine)Fibrinolytic agentTissue plasminogen activatorInternal medicineCardiologyMyocardial infarction

Abstract

fetched live from OpenAlex

Introduction: The tenecteplase versus standard of care for minor ischemic stroke with proven occlusion (TEMPO-2) trial showed that patients presenting with minor deficits up to 12 h do not benefit from intravenous thrombolysis. The trial included patients with minor but disabling deficits, mainly beyond 4.5 h, if they were not eligible for standard-of-care thrombolysis. We aimed to determine if intravenous tenecteplase improves outcomes in this subgroup of TEMPO-2 patients with disabling deficits. Methods: This was an exploratory secondary analysis of the TEMPO-2 trial, which randomized patients across 48 hospitals globally with minor acute ischemic stroke (NIHSS score 0-5) and intracranial occlusion or focal perfusion abnormality within 12 h from stroke onset to intravenous tenecteplase (0.25 mg/kg) or non-thrombolytic standard of care. Adopting an available definition for disabling stroke from the TREAT Task Force consensus (Table 1), we compared efficacy and safety outcomes between treatment arms for participants with non-disabling versus disabling syndromes at presentation. Results: Among 886 patients, 786 (88.7%) and 100 (11.3%) were identified to have non-disabling and disabling deficits, respectively. Patients with disabling deficits had higher baseline NIHSS scores (4 vs 2, P<0.001), later presentations (288min vs 133min, P<0.001) and longer onset to treatment time (411min vs 278min, P<001). There was no evidence of treatment effect heterogeneity between disabling and non-disabling groups (P interaction = 0.22). However, there were nominally fewer excellent outcomes at 90 days (mRS 0-1) with tenecteplase compared with standard of care in the disabling group (non-disabling: 72.0% vs 72.5%, P=0.936; disabling: 47.2% vs 61.7%, P=0.164). No difference in symptomatic ICH was found but an interaction existed with treatment arms and presence of disabling stroke regarding any hemorrhage on follow-up neuroimaging (non-disabling: tenecteplase 13.5% vs control 10.0%, P=0.146; disabling: tenecteplase 20.8% vs control 2.1%, P=0.005. P interaction = 0.049). Conclusions: The TREAT Task Force definition of disabling stroke did not modify the neutral treatment effect of intravenous tenecteplase in patients with minor stroke and intracranial occlusion. Fewer excellent outcomes after intravenous tenecteplase were observed in the disabling deficits group, possibly due to longer times to presentation and thrombolysis for the disabling subgroup.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.008
Threshold uncertainty score0.027

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.005
Meta-epidemiology (narrow)0.0020.000
Meta-epidemiology (broad)0.0030.004
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0080.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.015
GPT teacher head0.286
Teacher spread0.271 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueStroke→Same topicAcute Ischemic Stroke Management→French-language works237,207→